Clinical trials: sponsored by ANRS, Emerging Infectious Diseases
HIV, Tuberculosis
Improving Diagnosis of Tuberculosis in HIV Infected Children in Asia (Cambodia, Vietnam)and Africa (Burkina Faso, Cameroon)
Childhood tuberculosis (TB) accounts for 11% of the total 9 million annual TB cases and the difficulty of its diagnosis is increased in case of HIV infection in children.
- Conditions
- HIV, Tuberculosis, Pediatrics
- Trial name
- NCT01331811
- Testing
- Development of a diagnosis algorithm
- Where
- 8 sites in Burkina Faso, Cambodia and 2 more
- Volunteers
- 441 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV Infected Women, Healthy Women Volunteers
Study of Immunity at the Genital Mucosa of HIV-1 Infected and Healthy Women
Current knowledge on mucosa, especially genitals in women, however, remain inadequate, especially regarding defense mechanisms and possibilities for a vaccine to induce an active immune response at mucosal front door of the most…
- Trial name
- MUCOVAC (NCT01715103)
- Testing
- vaginal swabs by washing and cytobrush
- Where
- 2 sites in France
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
Hepatitis C
Qualification of Point-of-Care Assays for Management of HCV Patients
Acute or chronic HCV infection can lead to liver complications, including liver failure, cirrhosis or liver cancer. For patients with hepatitis C infection, the major clinical question remains the terms of treatment initiation.
- Trial name
- ANRS HC POC (NCT02335320)
- Where
- France
- Volunteers
- 250 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV Infection, Hepatitis B
Isolated Anti-HBc Serological Profile in HIV Infected Patients: Immunological, Virological Characteristics and Response to Hepatitis B Vaccination
The aim of study is to describe the clinical, immunological, serological, virological and therapeutic characteristics of HIV+ patients harboring isolated anti-HBc profile and to assess the response to vaccination in these…
- Trial name
- ANRSHBEP03 (NCT02323308)
- Testing
- blood sampling
- Where
- France
- Volunteers
- 55 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HCV Coinfection, HIV-1 Infection
Boceprevir in HIV-HCV Coinfected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin
The majority of Human immunodeficiency Virus (HIV)/Hepatitis C Virus (HCV) co-infected patients are non responders after 48 weeks of the current standard-of-care with Peg-Interferon/Ribavirin.
- Trial name
- BocepreVIH (NCT01335529)
- Testing
- Boceprevir, Peg-interferon alfa 2b and Ribavirin
- Where
- France
- Volunteers
- 69 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HCV-HIV Co-Infection
Pilot Study to Assess the Efficacy of and Tolerance to a QUadruple Therapy to Treat HIV-HCV Coinfected Patients Previously Null Responders
Evaluation of efficacy and tolerance to a QUadruple therapy with Asunaprevir , Daclatasvir, Ribavirin and pegylated Interferon alpha-2a, in HIV-HCV genotype 1 or 4 coinfected patients previously null responders to a standard…
- Trial name
- QUADRIH (NCT01725542)
- Testing
- Asunaprevir, Daclatasvir, Ribavirin and Peginterferon alfa-2a
- Where
- France
- Volunteers
- 75 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Hepatitis C, Chronic, Liver Fibrosis
Interest of Ribavirin in the Maintenance Treatment of Liver Fibrosis Using Low Dose Pegylated Interferon alpha2b in Patients With Chronic Hepatitis C Non Responders to Previous Antiviral Therapy.
Patients with chronic hepatitis C who did not respond to previous antiviral treatment develop liver fibrosis leading to cirrhosis.
- Trial name
- NCT00323804
- Testing
- Peginterferon alfa-2b, Ribavirin
- Where
- 45 sites in Belgium, France
- Volunteers
- 372 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV Infections, Tobacco Dependence
Efficacy and Safety of Varenicline Among HIV-infected Patients
Cigarette smoking is a major cause of illness among HIV-infected patients (non-AIDS defining malignancies (especially lung cancer), non-AIDS bacterial infections and cardio-vascular diseases).
- Trial name
- Inter-ACTIV (NCT00918307)
- Testing
- Varenicline
- Where
- France
- Volunteers
- 248 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Chronic Hepatitis C
Evaluation of the National Treatment Program of Hepatitis C in Egypt
The aim of the study is to analyse data coming from two treatment centres of the National Treatment Program Centres of hepatitis C in Egypt
- Trial name
- eNTC (NCT02101177)
- Where
- 2 sites in Egypt
- Sponsor
- ANRS, Emerging Infectious Diseases
Chronic Hepatitis C
Observational Study of B-Cell Non Hodgkin Lymphomas (NHL) Associated With Hepatitis C Virus (HCV)
An prospective / retrospective multicenter observational study whose objectives are to understand the interactions between hepatitis c virus and Non Hodgkin lymphomas.
- Trial name
- Lympho C (NCT01545544)
- Where
- France
- Volunteers
- 138 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV-1 Infections
Optimisation of Primary HIV1 Infection Treatment(ANRS 147 OPTIPRIM)
The purpose of this trial is to assess the impact of raltegravir, maraviroc, darunavir/r, and Truvada® (emtricitabine/tenofovir) vs.
- Trial name
- NCT01033760
- Testing
- raltegravir; maraviroc; darunavir; ritonavir; tenofovir/emtricitabine, darunavir; ritonavir; emtricitabine/tenofovir
- Where
- France
- Volunteers
- 90 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV Infections
Study of Darunavir/r + Tenofovir/Emtricitabine vs. Darunavir/r + Raltegravir in HIV-infected Antiretroviral naïve Subjects
The triple therapy darunavir/r + tenofovir/emtricitabine is likely to become a relevant first-line treatment option in the years to come.
- Trial name
- ANRS 143 (NCT01066962)
- Testing
- darunavir/ritonavir QD + raltegravir BID, darunavir/r QD + tenofovir/emtricitabine QD (fixed dose combination)
- Where
- 77 sites in Austria, Belgium and 13 more
- Volunteers
- 800 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV Infections, Tuberculosis
Efficacy and Safety of 2 Raltegravir Doses in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis
Raltegravir is a potent antiretroviral agent that could be used as an alternative to efavirenz in HIV-1 infected patients with tuberculosis.
- Trial name
- NCT00822315
- Testing
- efavirenz, raltegravir
- Where
- 9 sites in Brazil, France
- Volunteers
- 155 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Chronic Hepatitis B, AgHbs Negativation
A Randomized Study to Assess the Loss of HbsAg After a 48-week Treatment Period With Pegylated Interferon Alpha 2a in Patients With Chronic Hepatitis B
The purpose of this study is to assess the loss of HbsAg after a 48-week pegylated interferon alpha 2a in patients with chronic hepatitis B (HBeAg negativation)
- Trial name
- PEGAN (NCT01172392)
- Testing
- Pegylated interferon-alpha-2a, Nucleotidic or Nucleosidic Treatment
- Where
- France
- Volunteers
- 185 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV
A Multicentre Trial of Second-line Antiretroviral Treatment Strategies in African Adults Using Atazanavir or Lopinavir/Ritonavir
In the well recognized context of HIV infection chronicity, it is now crucial to identify and evaluate effective, well tolerated and affordable second line regimen in resources limited countries where patients often change…
- Trial name
- ALISA (NCT01255371)
- Testing
- Lopinavir, Atazanavir
- Where
- 2 sites in South Africa, Tanzania
- Sponsor
- ANRS, Emerging Infectious Diseases